Beijing Mayor Visited Sinovac on Promoting Development of Biopharmaceutical Industry

2009-04-27

In the morning of April 22^nd, 2009, Beijing government officers , Qi Liu, Jinlong Guo, Anshun Wang, Shixiang Li, Fengtong Zhao, Zhongwen Gou, Xiangyang Ding and other officers from relative governmental departments, total more than 40 governors, came to Sinovac to perform the specific research related to “Improve the capability of independent innovation and promote the development of biopharmaceutical industry” on pharmaceutical industry and academic organizations. They were accompanied by the head of Administrative Committee of Zhongguancun Science Park, Wei Dai, the head of Haidian Chinese Communist Party Committee, Weike Tan, the head of Haidian District Government, Fusheng Lin, etc.

In the filling & packaging plant of Sinovac, officers inspected two modern packaging lines and learned the manufacturing process. Sinovac CEO, Weidong Yin reported Sinovac’s R&D and industrialization projects to these officers, and introduced the situation of current operation and future development plan as well as the focus of investment under the economic crisis. Weidong Yin said, “Developing towards an enterprise group is our goal. We have to contribute our efforts to the aim of Beijing development.

After reporting, Qi Liu and other government officers discussed with Weidong Yin about building up Zhongguancun National Innovation Park, the tax policy about companies’ re-investment and the development of biopharmaceutical industry.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com